SEARCH

SEARCH BY CITATION

References

  • 1
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S98S.
  • 2
    Rose AJ, Ozonoff A, Grant RG, Henault LE, Hylek EM. The epidemiology of sub-therapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2: 5917.
  • 3
    Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893900.
  • 4
    Rosendaal FR, Cannegieter SC, Van Der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 2369.
  • 5
    White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 23945.
  • 6
    Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practice. J Thromb Haemost 2008; 6: 164754.
  • 7
    United States Department of Veterans Affairs. 2009 Annual Performance and Accountability Report. http://www4.va.gov/budget/report. Accessed 25 May 2010.
  • 8
    United States Department of Veterans Affairs. VHA Directive 2009-003. Anticoagulation Therapy Management. 2 February 2009.
  • 9
    Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 268592.
  • 10
    Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 202937.
  • 11
    Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf 2009; 35: 14655.
  • 12
    Little RJA, Rubin DB. Statistical Analysis with Missing Data. Hoboken, NJ: Wiley, 2002.
  • 13
    United States Census Bureau. United States Census 2000. http://www.census.gov/main/www/cen2000.html. Accessed 20 November 2009.
  • 14
    Krieger N, Waterman PD, Chen JT, Rehkopf DH, Subramanian SV. Geocoding and monitoring US socioeconomic inequalities in health: an introduction to using area-based socioeconomic measures – The Public Health Disparities Geocoding Project monograph. http://www.hsph.harvard.edu/thegeocodingproject/. Accessed 1 April 2010.
  • 15
    Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR. Identifying hypertension-related comorbidities from administrative data: what’s the optimal approach? Am J Med Qual 2004; 19: 2016.
  • 16
    Szeto HC, Coleman RK, Gholami P, Hoffman BB, Goldstein MK. Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. Am J Manag Care 2002; 8: 3743.
  • 17
    Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med 2007; 22: 9971002.
  • 18
    Van Walraven C, Austin PC, Oake N, Wells P, Mamdani M, Forster AJ. The effect of hospitalization on oral anticoagulation control: a population-based study. Thromb Res 2007; 119: 70514.
  • 19
    Bhandari VK, Wang F, Bindman AB, Schillinger D. Quality of anticoagulation control: do race and language matter? J Health Care Poor Underserved 2008; 19: 4155.
  • 20
    Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006; 37: 10704.
  • 21
    Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke 2008; 39: 273643.
  • 22
    Fang MC, Machtinger EL, Wang F, Schillinger D. Health literacy and anticoagulation-related outcomes among patients taking warfarin. J Gen Intern Med 2006; 21: 8416.
  • 23
    Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, Marchetti G, Poli D, Pengo V. Risk factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005; 129: 728.
  • 24
    Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes, 3rd edn. Chicago, IL: Health Administration Press, 2003.
  • 25
    Hart RG, Pearce LA, Aguillar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 85767.
  • 26
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 27
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 234252.
  • 28
    O’Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005; 293: 699706.
  • 29
    Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985; 313: 7939.
  • 30
    Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 1997; 277: 48894.